Late Onset Neutropenia and Immunoglobulin Suppression of the Patients with Malignant Lymphoma Following Autologous Stem Cell Transplantation with Rituximab

被引:21
作者
Hirayama, Yasuo [1 ,3 ]
Kohda, Kyuhei [1 ]
Konuma, Yuichi [1 ]
Hirata, Yasuji [2 ]
Kuroda, Hiroyuki [1 ,3 ]
Fujimi, Yuko [4 ]
Shirao, Sayaka [4 ]
Kobune, Masayoshi [4 ]
Takimoto, Rishu [4 ]
Matsunaga, Takuya [4 ]
Kato, Junji [4 ]
机构
[1] Asahikawa Red Cross Hosp, Dept Hematol & Oncol, Asahikawa, Hokkaido, Japan
[2] Hakodate Red Cross Hosp, Dept Internal Med, Hakodate, Hokkaido, Japan
[3] Higashi Sapporo Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan
[4] Sapporo Med Univ, Dept Internal Med 4, Sapporo, Hokkaido, Japan
关键词
rituximab; transplantation; neutropenia; immunoglobulin; THERAPY;
D O I
10.2169/internalmedicine.48.1368
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recently, decrease of immunoglobulin concentrations or neutrophil counts were reported in some cases several months after administration of rituximab. We examined a number of episodes of late onset neutropenia or immunoglobulin decrease in patients with malignant lymphoma who were in complete remission following autologous transplantation with or without rituximab. Method Patients with follicular lymphoma and diffuse large B cell lymphoma transplanted with or without rituximab in our institutes were analyzed. Immunoglobulin concentrations and neutrophil counts after transplantation, both with and without rituximab were measured serially. Results Four weeks after transplantation, blood samples revealed lower concentrations of IgG and IgA in the rituximab group than in the non-rituximab group. Neutrophil numbers did not fall below 0.5x10(9)/L four weeks or more after transplantation in the non-rituximab group. Neutrophil numbers dropped below 0.5x10(9)/L in 6 of 14 cases in the rituximab group. Conclusion Although the present study was retrospective and disease composition and pre-transplantation regimens differed between the two groups, the addition of rituximab to autologous transplantation might bring about a decrease of immunoglobulin levels and transient LON.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 11 条
  • [1] Cairoli R, 2004, HAEMATOLOGICA, V89, P361
  • [2] Delayed-onset neutropenia associated with rituximab therapy
    Chaiwatanatorn, K
    Lee, N
    Grigg, A
    Filshie, R
    Firkin, F
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) : 913 - 918
  • [3] B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis
    Dunleavy, K
    Hakim, F
    Kim, HK
    Janik, JE
    Grant, N
    Nakayama, T
    White, T
    Wright, G
    Kwak, L
    Gress, R
    Tosato, G
    Wilson, WH
    [J]. BLOOD, 2005, 106 (03) : 795 - 802
  • [4] Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL
    Flohr, T
    Hess, G
    Kolbe, K
    Gamm, H
    Nolte, H
    Stanislawski, T
    Huber, C
    Derigs, HG
    [J]. BONE MARROW TRANSPLANTATION, 2002, 29 (09) : 769 - 775
  • [5] Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment
    Klepfish, A.
    Rachmilevitch, E.
    Schattner, A.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2006, 17 (07) : 505 - 507
  • [6] MACOP-B CHEMOTHERAPY FOR THE TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA
    KLIMO, P
    CONNORS, JM
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 102 (05) : 596 - 602
  • [7] Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma
    Lemieux, B
    Tartas, S
    Traulle, C
    Espinouse, D
    Thieblemont, C
    Bouafia, F
    Alhusein, Q
    Antal, D
    Salles, G
    Coiffier, B
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (09) : 921 - 923
  • [8] Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: Case report and literature review
    Motl, SE
    Baskin, RC
    [J]. PHARMACOTHERAPY, 2005, 25 (08): : 1151 - 1155
  • [9] Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia
    Nishio, M
    Endo, T
    Fujimoto, K
    Sato, N
    Sakai, T
    Obara, M
    Kumano, K
    Minauchi, K
    Koike, T
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (06) : 527 - 529
  • [10] Rituximab-associated immune myelopathy
    Papadaki, T
    Stamatopoulos, K
    Anagnostopoulos, A
    Fassas, A
    [J]. BLOOD, 2003, 102 (04) : 1557 - 1558